- Home
- EOSE vs BEAM Comparison
EOSE vs BEAM Comparison
Compare EOSE & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOSE
- BEAM
- Stock Information
- Founded
- EOSE 2008
- BEAM 2017
- Country
- EOSE United States
- BEAM United States
- Employees
- EOSE N/A
- BEAM N/A
- Industry
- EOSE Industrial Machinery/Components
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EOSE Miscellaneous
- BEAM Health Care
- Exchange
- EOSE Nasdaq
- BEAM Nasdaq
- Market Cap
- EOSE 2.3B
- BEAM 2.6B
- IPO Year
- EOSE N/A
- BEAM 2020
- Fundamental
- Price
- EOSE $16.14
- BEAM $27.84
- Analyst Decision
- EOSE Buy
- BEAM Strong Buy
- Analyst Count
- EOSE 5
- BEAM 11
- Target Price
- EOSE $12.30
- BEAM $49.40
- AVG Volume (30 Days)
- EOSE 26.1M
- BEAM 2.5M
- Earning Date
- EOSE 11-04-2025
- BEAM 11-05-2025
- Dividend Yield
- EOSE N/A
- BEAM N/A
- EPS Growth
- EOSE N/A
- BEAM N/A
- EPS
- EOSE N/A
- BEAM N/A
- Revenue
- EOSE $33,800,000.00
- BEAM $60,272,000.00
- Revenue This Year
- EOSE $857.58
- BEAM N/A
- Revenue Next Year
- EOSE $225.49
- BEAM $19.01
- P/E Ratio
- EOSE N/A
- BEAM N/A
- Revenue Growth
- EOSE 128.49
- BEAM N/A
- 52 Week Low
- EOSE $2.06
- BEAM $13.53
- 52 Week High
- EOSE $19.05
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- EOSE 61.88
- BEAM 57.97
- Support Level
- EOSE $14.19
- BEAM $26.90
- Resistance Level
- EOSE $17.33
- BEAM $31.54
- Average True Range (ATR)
- EOSE 1.66
- BEAM 2.15
- MACD
- EOSE -0.22
- BEAM -0.03
- Stochastic Oscillator
- EOSE 49.83
- BEAM 53.68
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.